2025
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database. Annals Of Hematology 2025, 104: 2507-2515. PMID: 40102305, PMCID: PMC12052795, DOI: 10.1007/s00277-025-06307-z.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcquired Aplastic AnemiaCalcineurin inhibitorsParoxysmal nocturnal hemoglobinuriaTransfusion-DependentTriple therapyAA patientsAplastic anemiaAllogeneic hematopoietic stem cell transplantationTreated with calcineurin inhibitorsTreated with antithymocyte globulinFlow cytometryInitial management of patientsSevere AA patientsStem cell transplantationBone marrow failureImmune-mediated disordersTreatment initiation delayRetrospective cohort studyManagement of patientsDiagnosis to treatmentNational claims databaseAntithymocyte globulinSibling donorMarrow failure
2024
Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.Peer-Reviewed Original ResearchSevere aplastic anemiaTreatment of severe aplastic anemiaQuality-adjusted life yearsAplastic anemiaIncremental net monetary benefitDeterministic sensitivity analysisProbabilistic sensitivity analysesImmunosuppressive therapyNewly diagnosed severe aplastic anemiaCost-effectiveness of eltrombopagOral thrombopoietin receptor agonistPatients treated with eltrombopagUntreated severe aplastic anemiaHematopoietic stem cell transplantationCost-effective therapeutic strategyDevelopment of adverse eventsLonger-term follow-up dataRACE trialsLater-line therapyThrombopoietin receptor agonistsPhase I/II trialSecond-line therapyStem cell transplantationU.S. payer perspectiveFirst-line treatmentAplastic anemia in association with multiple myeloma: clinical and pathophysiological insights
Muradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, 65: 2182-2189. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.Peer-Reviewed Original ResearchAplastic anemiaMultiple myelomaImmunosuppressive therapyTransfusion requirementsProgenitor cellsPlasma cell-directed therapyT-cell destructionCell-directed therapiesInhibition of erythroid colony formationErythroid colony formationLevels of IL8Severe AAImmune cytopeniasPartial responseMM patientsHematopoietic stemSerum testsPartial improvementPathophysiological insightsPatientsImmune systemPlatelet apoptosisCytopeniasColony formationMyeloma
2022
Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature
Belzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics 2022, 11: 1398. PMID: 36290055, PMCID: PMC9598652, DOI: 10.3390/antibiotics11101398.Peer-Reviewed Original ResearchSoft tissue infectionsUrinary tract infectionChronic lymphocytic leukemiaGram-negative bacilliTract infectionsImmunocompetent populationTissue infectionsHigh morbidityAplastic anemiaCase reportLymphocytic leukemiaInfectionBacteremiaCurrent standardStenotrophomonas maltophiliaDermatologistsLimited optionsMorbidityPneumoniaPatientsAnemiaTherapyLeukemiaMortalityPrevalence
2020
Transplant in aplastic anemia using combined G-CSF primed blood and bone marrow stem cells – a retrospective analysis
Ali N, Butt A, Altaf B, Adil S, Shaikh U. Transplant in aplastic anemia using combined G-CSF primed blood and bone marrow stem cells – a retrospective analysis. Hematology Transfusion And Cell Therapy 2020, 42: 63. DOI: 10.1016/j.htct.2020.09.113.Peer-Reviewed Original ResearchTransplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis
Ali N, Butt A, Altaf B, Adil SN, Shaikh MU. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis. Transplantation Proceedings 2020, 53: 386-390. PMID: 32773285, DOI: 10.1016/j.transproceed.2020.06.035.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnemia, AplasticChildChild, PreschoolFemaleGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationPostoperative ComplicationsRetrospective StudiesTransplantation ConditioningYoung AdultConceptsBone marrow stem cellsAplastic anemiaMarrow stem cellsOverall survivalAntithymocyte globulinAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantStem cellsStudy periodFrequency of GVHDHost disease (GVHD) prophylaxisStandard infection prophylaxisOnly curative optionBone marrow graftsStem cell transplantGranulocyte colony-stimulating factorColony-stimulating factorAga Khan UniversityAcute GVHDChronic GVHDConditioning regimenCurative optionTransplant outcomesAllogeneic transplantsConditioning regimens
2018
Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts
Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. European Journal Of Haematology 2018, 101: 711-720. PMID: 30055055, DOI: 10.1111/ejh.13153.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAplastic anemiaMolecular pathogenesisDevelopment of AAStem cell injuryHematopoietic stem cell injuryT cell homeostasisTelomerase complex genesBone marrow failureLikely autoimmuneMarrow featuresPeripheral cytopeniasPathologic featuresPatient outcomesMonosomy 7Rare disorderAA pathogenesisCell injuryPathogenic mechanismsTrisomy 8Clonal diseaseCytogenetic abnormalitiesPathogenesisMarrow failureDiseaseUniparental disomyImmunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place
Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmunosuppressive therapyMyelodysplastic syndromeImmune pathwaysManagement of MDSTreatment of MDSClonal hematopoietic stem cell disordersMeaningful clinical activityAdaptive immune pathwaysHematopoietic stem cell disordersStem cell disordersImmune dysregulationDisease coursePeripheral cytopeniasClinical benefitImmune activationTherapeutic optionsAplastic anemiaClinical activityHematologic diseasesCell disordersClinical experienceContinued clarificationLeukemic progressionTherapyPatients
2016
Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016
Zeidan AM, Battiwalla M, Berlyne D, Winkler T. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. Leukemia Research 2016, 53: 8-12. PMID: 27923195, PMCID: PMC7731993, DOI: 10.1016/j.leukres.2016.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow failure syndromesMDS International FoundationAplastic anemiaPeripheral blood cytopeniasAcute myelogenous leukemiaMarrow failure syndromesBlood cytopeniasCommon manifestationIneffective hematopoiesisMyelogenous leukemiaFailure syndromeClinical implicationsHematopoietic stem cell compartmentStem cell compartmentPatientsAnemiaCell compartmentFamily membersIndependent nonprofit organizationInternational FoundationCytopeniasSyndromePathogenesisLeukemia
2014
Cluster and Sporadic Cases of Herbaspirillum Species Infections in Patients With Cancer
Chemaly R, Dantes R, Shah D, Shah P, Pascoe N, Ariza-Heredia E, Perego C, Nguyen D, Nguyen K, Modarai F, Moulton-Meissner H, Noble-Wang J, Tarrand J, LiPuma J, Guh A, MacCannell T, Raad I, Mulanovich V. Cluster and Sporadic Cases of Herbaspirillum Species Infections in Patients With Cancer. Clinical Infectious Diseases 2014, 60: 48-54. PMID: 25216687, PMCID: PMC4318942, DOI: 10.1093/cid/ciu712.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAgedBetaproteobacteriaBurkholderia cepaciaChild, PreschoolCluster AnalysisCross InfectionDNA, BacterialDNA, RibosomalElectrophoresis, Gel, Pulsed-FieldFemaleGenotypeGram-Negative Bacterial InfectionsHerbaspirillumHumansMaleMiddle AgedMolecular TypingNeoplasmsRetrospective StudiesRNA, Ribosomal, 16SSequence Analysis, DNAConceptsPulsed-field gel electrophoresisAvailable isolatesComprehensive cancer centerHospital-based clusterDifferent PFGE patternsIntravenous antibioticsUnderlying diagnosisSymptomatic patientsProspective surveillanceBloodstream infectionsAplastic anemiaCancer CenterCase findingPatientsSolid tumorsSporadic casesSpecies infectionInfectionPrevention assessmentBurkholderia cepaciaPFGE patternsSubsequent casesSepsisFacility observationsRibosomal DNA sequencing
2010
Risks and outcome of fungal infection in neutropenic children with hematologic diseases.
Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S. Risks and outcome of fungal infection in neutropenic children with hematologic diseases. The Turkish Journal Of Pediatrics 2010, 52: 121-5. PMID: 20560245.Peer-Reviewed Original ResearchConceptsFebrile neutropenic episodesAcute myeloid leukemiaNeutropenic episodesAcute lymphoblastic leukemiaAplastic anemiaAntifungal treatmentFungal infectionsMortality rateAmphotericin BNeutropenic childrenRetrospective studyLymphoblastic leukemiaMyeloid leukemiaHematologic diseasesTreatment groupsPatientsWhole groupInfectionEpisodesLeukemiaMortalityAnemiaGroupDiseaseFluconazole
1998
Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant
Seropian S, Ferguson D, Salloum E, Cooper D, Landry M. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplantation 1998, 22: 507-509. PMID: 9733277, DOI: 10.1038/sj.bmt.1701354.Peer-Reviewed Original ResearchConceptsPeripheral blood leukocytesAntigenemia testingCMV diseaseCMV infectionAntiviral therapyBlood leukocytesPre-emptive antiviral therapyAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAntibody poolEarly detectionCMV pp65 antigenemiaBone marrow transplantationBone marrow transplantPeripheral blood specimensPeripheral blood samplesAllogeneic BMTLiver transaminasesPp65 antigenemiaAbnormal transaminasesMarrow transplantationMarrow transplantViral cultureAplastic anemiaBronchial lavage
1995
Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis.
Vazquez J, Lundstrom T, Dembry L, Chandrasekar P, Boikov D, Parri M, Zervos M. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplantation 1995, 16: 849-53. PMID: 8750282.Peer-Reviewed Original ResearchConceptsHigh-dose amphotericin BMinimum inhibitory concentration (MIC) rangeSustained neutropeniaPurulent pericarditisAplastic anemiaC. guilliermondiiInhibitory concentration rangePoor responseClinical isolatesAmphotericin BProlonged durationHigh MICsInitial misidentificationTherapyEnvironmental isolatesIsolatesControl strainMolecular analysisNeutropeniaPericarditisFungemiaAnemiaBMTFlucytosineAmB
1988
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome.
Antin J, Smith B, Holmes W, Rosenthal D. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988, 72: 705-13. PMID: 3042046, DOI: 10.1182/blood.v72.2.705.bloodjournal722705.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnemia, AplasticBlood Cell CountBone MarrowCell DivisionColony-Stimulating FactorsDose-Response Relationship, DrugDrug EvaluationFemaleGranulocyte-Macrophage Colony-Stimulating FactorGrowth SubstancesHumansMaleMiddle AgedMyelodysplastic SyndromesRecombinant ProteinsReticulocytesConceptsPhase I/II studyRecombinant human granulocyte-macrophage colony-stimulating factorAplastic anemiaGranulocyte-macrophage colony-stimulating factorMyelodysplastic syndromeColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorII studyReticulocyte countErythrocyte transfusion requirementsLow-grade feverMyalgia/arthralgiaMicrograms/m2Four-hour intravenous infusionNumber of eosinophilsGM-CSF therapyImmature myeloid cellsLow back discomfortTransfusion requirementsBlood countIntravenous infusionPlatelet countGranulocyte countMonocyte countPatientsPhase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Antin JH, Smith BR, Holmes W, David RN, Rosenthal S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Institute Mitteilungen 1988, 149-53. PMID: 3071331.Peer-Reviewed Original ResearchConceptsPhase I/II studyMicrograms/m2Bone marrow failureII studyMarrow failureGM-CSFSevere bone marrow failureErythrocyte transfusion requirementsMyalgia/arthralgiaLow-grade feverRecombinant human granulocyte-macrophage colony-stimulating factorGranulocyte-macrophage colony-stimulating factorSevere marrow failureLow back discomfortColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorRecombinant human GM-CSFGrade feverTransfusion requirementsIntravenous infusionMyelodysplastic syndromePlatelet countAplastic anemiaGranulocyte countMonocyte countPhase I/II Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Aplastic Anemia and Myelodysplastic Syndrome
Antin J, Smith B, Holmes W, Rosenthal D. Phase I/II Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Aplastic Anemia and Myelodysplastic Syndrome. Blood 1988, 72: 705-713. DOI: 10.1182/blood.v72.2.705.705.Peer-Reviewed Original ResearchPhase I/II studyAplastic anemiaMyelodysplastic syndromeII studyReticulocyte countErythrocyte transfusion requirementsLow-grade feverMyalgia/arthralgiaMicrograms/m2Four-hour intravenous infusionRecombinant human granulocyte-macrophage colony-stimulating factorNumber of eosinophilsGM-CSF therapyImmature myeloid cellsGranulocyte-macrophage colony-stimulating factorRecombinant human granulocyte-macrophage colonyLow back discomfortColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorGranulocyte-macrophage colonyTransfusion requirementsIntravenous infusionPlatelet countBlood countGranulocyte count
1985
EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA
Smith BR, Guinan EC, Parkman R, Ferrara J, Levey RH, Nathan DG, Rappeport JM. EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA. Transplantation 1985, 39: 671-672. PMID: 3890295, DOI: 10.1097/00007890-198506000-00020.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply